Efficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational studyObservational Study Published on 2022-09-022022-10-05 Journal: PLoS ONE [Category] SARS, 임상, 진단, [키워드] adverse event Anaphylactic reaction antibody BNT162b2 combination therapy COVID-19 COVID-19 pandemic dose Efficacy and safety eligible patient evaluate evaluated event geometric group Health immunosuppressive indicated Inflammatory bowel disease Local majority MONITOR Patient patients Prospective prospective observational study SARS-CoV-2 SARS-CoV-2 IgG antibody SARS-CoV-2 vaccination significant difference therapy treated U/mL vaccination vaccination against COVID-19 Vaccine vaccine administration [DOI] 10.1371/journal.pone.0273612 PMC 바로가기 [Article Type] Observational Study
Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patientsArticle Published on 2022-09-012023-06-13 Journal: Journal of viral hepatitis [Category] B형 간염, [키워드] chronic combination therapy HBsAg loss hepatitis B nucleos(t)ide analogues Pegylated interferon [DOI] 10.1111/jvh.13722
Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessmentSARS-CoV-2에 대한 항 HIV 약물 및 식물성 플라보노이드 조합: 분자 도킹 시뮬레이션 기반 평가Article Published on 2022-09-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 치료제, [키워드] acute respiratory syndrome Analysis anti-HIV drug anti-HIV drugs Anti-inflammatory antimalarial drug Antimalarial drugs Antiviral clinical evidence Combination combination therapy combined effect complex coronavirus darunavir docking docking score drug drug-likeness eight enzyme flavonoid genome replication H-bond Health Hypothesis in viral individual Ligand ligands M pro MM/PBSA molecular molecular docking Molecular docking study molecular docking-simulation Patient phyto-flavonoid prophylactic therapy protease Protease inhibitor quercetin respiratory RMSF SARS-CoV-2 selected selective Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 stability viral genome replication [DOI] 10.1080/07391102.2021.1885495 PMC 바로가기 [Article Type] Article
In-silico study for the screening and preparation of ionic liquid-AVDs conjugate to combat COVID-19 surgeResearch article Published on 2022-08-012022-10-05 Journal: The British journal of oral & maxillofacial surger [Category] 변종, 신약개발, 치료제, [키워드] abacavir acyclovir ADME Analysis Antiviral antiviral activity antiviral drug antiviral drugs binding energy blind caused Combination combination therapy complex conjugate Conjugates COVID-19 death DFT Diseases drug effective greater Ionic liquids MD simulation molecular molecular docking MPro pandemic performed protease recorded SARS-CoV-2 screened stability suggested target protein therapeutic Toxicity was done were used [DOI] 10.1016/j.molliq.2022.119277 [Article Type] Research article
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy면역억제 요법을 받는 환자에서 표준 및 3차 접종 SARS-CoV-2 백신 접종의 면역원성과 안전성Observational Study Published on 2022-08-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adult patient adverse event age antibody arbitrary unit characterized combination therapy comparable Control controls defined disease dose evaluate facilitate full-length healthy healthy control healthy controls IgG antibody Immune-mediated inflammatory disease immunogenicity immunosuppressive inhibitor interquartile range jak inhibitors lowest median Necrosis Patient patient group patients performed predictor proportion prospective observational study psoriatic arthritis RBD receiving regimen Responder responders rheumatoid arthritis risk RNA-1273 Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serologic response Spike protein spondyloarthritis Standard Support the receptor-binding domain the SARS-CoV-2 therapy ulcerative colitis vaccination Vaccine vaccine dose vaccine response [DOI] 10.1002/art.42153 PMC 바로가기 [Article Type] Observational Study
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments알츠하이머병(NorAD)에서 연장 방출 구안파신을 사용한 노르아드레날린성 추가 요법: 무작위 임상 시험 및 COVID-19 수정안에 대한 연구 프로토콜Article Published on 2022-08-012022-09-11 Journal: Trials [Category] 임상, [키워드] activities activity Add-on therapy addition Adrenergic receptor affected Alzheimer's disease Alzheimer’s disease approved assessment Attention attention deficit baseline Brain burden cholinesterase inhibitor clinical trial Cognition cognitive Combination combination therapy COVID-19 Daily daily living determine disease disorder double-blind dysfunction evaluate Evidence executive Follow-up function Guanfacine Guanfacine. hyperactivity IMPROVE include interview inventory involved locus measure Mild mild to moderate moderate modulating Neuropsychiatric NorAD noradrenergic observation outcome participant pathological change pathological changes pathway Pathways Placebo placebo group placebo-controlled Primary outcome randomised receive receptor Regulation secondary Secondary outcomes Study protocol Symptom symptomatic synergistic synergistic effect Test the placebo group thought Treatment treatment group Trial [DOI] 10.1186/s13063-022-06190-3 PMC 바로가기 [Article Type] Article
Clinical Effect of Early administration of Tocilizumab Following the Initiation of Corticosteroid Therapy for Patients with COVID-19Article Published on 2022-08-012022-10-05 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome addition administration analyzed baseline blood cell count C-reactive protein caused clinical Clinical characteristics combination therapy coronavirus Corticosteroid corticosteroid therapy corticosteroid treatment Corticosteroids COVID-19 determine drug early administration Effect effective Efficacy evaluated global pandemic groups hospital Hospitalized Initiation maximum body temperature not significantly different oxygen-free day Patient patients with COVID-19 Result SARS-CoV-2 significant decrease significantly higher significantly lower significantly more survival rate Tocilizumab tocilizumab administration treated treating COVID-19 two groups white with COVID-19 Wuhan [DOI] 10.1016/j.jiac.2022.08.021 [Article Type] Article
Immune therapies against chronic hepatitis BReview Published on 2022-08-012023-06-12 Journal: Journal of Gastroenterology [Category] B형 간염, Fulltext, [키워드] Antigen-specific immunotherapy Chronic Hepatitis B combination therapy immune therapy Polyclonal immune modulators. [DOI] 10.1007/s00535-022-01890-8 PMC 바로가기 [Article Type] Review
Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19COVID-19의 역할을 포함한 횡문근 융해 유발 AKI(RIAKI)Review Published on 2022-07-262022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), MERS, SARS, 바이오마커, 치료기술, [키워드] acute kidney Acute kidney injury acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration AKI aspartate Aspartate aminotransferase AST bloodstream caused Cell combination therapy Complication contribute coronavirus Course COVID-19 COVID-19 disease creatine creatine kinase damage defined develop Diagnosis disease drugs escape Factors FIVE Fluid resuscitation furosemide high mortality rate in some Including Lactate lactate dehydrogenase LDH life-threatening limit mannitol many cases marker muscle pain Myoglobin occur Pain Patient patients Potassium renal renal replacement therapy replacement therapy required respiratory rhabdomyolysis role RRT SARS-CoV-2 serious complication serum severe acute respiratory syndrome Coronavirus Side effect Side effects sodium sodium bicarbonate statin Striated muscle therapeutic interventions therapy Treatment uridine [DOI] 10.3390/ijms23158215 PMC 바로가기 [Article Type] Review
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial